XBiotech Inc.

NASDAQ:XBIT

Biotechnology

Healthcare
$1.73 -0.84%

-$0.02 today

Market cap
$52.74M
Beta
0.84
P/E (TTM)
-1.8
EPS (TTM)
-$1.32
52W Low $2.09High $3.61

Volume 0.06M

Average 0.03M

XBIT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

XBiotech Inc.NASDAQ: XBIT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $5.21M fell 55.2% year over year, behind the +3.6% change in trailing-twelve-month research & development. Sequentially, it fell 79.5% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -55.2% toward the trailing-twelve-month pace of +3.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.21M-79.5% QoQ
Last fiscal yearDec 2025
$47.39M+25.5% YoY
LTMMar 2026
$40.98M+3.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.2%——
1 year+25.5%——
3-year CAGR+14.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
47.39M USD
Year-over-year change
+25.5%
4-year CAGR
+13.8%

Research & Development vs competitors

How XBIT compares with its peers on the latest reported figures

  • XBIT's LTM Mar 2026 research & development of $40.98M is the 4th highest of the 9 companies compared; the peer median is $26.55M.
  • Its year-over-year change of +3.6% is the highest of 8, against a peer median of -11.8%.
  • Over three fiscal years its annual growth of +14.5% compares with a peer median of +9.2%.
XBIT Competitors Peer median
Research & Development for XBIT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
ACETAdicet Bio, Inc.LTM Mar 2026$93.8M -4.5%+11.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
XBITXBiotech Inc.LTM Mar 2026$40.98M +3.6%+14.5%—
ADAGAdagene Inc.LTM Jun 2024$30.07M —-35.3%3686.7%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
GANXGain Therapeutics, Inc.LTM Mar 2026$10.72M +1.7%+6.8%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M -76.4%-55.5%12.9%
NTRBNutriband Inc.LTM Apr 2026$1.45M -48.6%+24.4%80.7%
Peer median (excluding XBIT) $26.55M-11.8%+9.2%621.9%

Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.39M4.01M000
Cost of Revenue5.82M651K001.69M
Gross Profit12.57M3.36M00(1.69M)
Gross Margin68.4%83.8%———
Research & Development28.27M31.54M32.85M37.76M47.39M
Selling, General & Admin9.39M6.31M4.66M4.71M8.3M
Operating Expenses37.66M37.85M37.51M42.47M54M
Depreciation & Amortization2.65M2.61M1.74M1.75M1.69M
EBITDA(22.81M)(30.97M)(22.57M)(36.01M)(43.53M)
EBITDA Margin-124.0%-772.4%———
Operating Income(25.08M)(34.49M)(37.51M)(42.47M)(55.69M)
Operating Margin-136.4%-860.1%———
Interest Income467K3.82M10.42M9.81M5.68M
Interest Expense000807K88K
Other Income / Expenses(376K)902K13.2M3.91M10.38M
Income Before Tax(25.46M)(33.59M)(24.31M)(38.56M)(45.31M)
Pre-Tax Margin-138.4%-837.6%———
Income Tax Expense(8.04M)(688K)244K(32K)235K
Net Income(17.41M)(32.9M)(24.56M)(38.53M)(45.54M)
Net Margin-94.7%-820.4%———
EPS (Basic)(0.58)(1.08)(0.81)(1.26)(1.49)
EPS (Diluted)(0.58)(1.08)(0.81)(1.26)(1.49)
Weighted Avg Shares30.04M30.44M30.32M30.46M30.49M
Weighted Avg Shares (Diluted)30.04M30.44M30.44M30.46M30.49M

XBiotech Inc.

NASDAQ:XBIT

Intrinsic Alpha fair value

Locked

Current Price

$1.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.